AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04458792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery radiotherapy toxicity : Blood samples collected before the radiotherapy
Study NCT01406444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhIGF-1
Description: Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
Study NCT01406444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Risedronate 35mg PO one time weekly
Study NCT01406444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
Study NCT00580580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optison
Description: 0.1-0.4 mL through intravenous injection at the beginning of the study.
Study NCT00580580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Definity
Description: intravenous injection at 0.05-0.20 mL
Study NCT00580580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PESDA
Description: intravenous injections dosage 0.05-0.20 mL
Study NCT04627324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The smart toothbrush and smart mirror (STM) system (XiuSolution, Gyeonggi-do, Korea)
Description: The STM system comprises a smart mirror, which is integrated into a computer monitor, and a 3D motion-capture device inside of a modified toothbrush holder. The computer program displays a toothbrushing animation in the mirror. Toothbrush motions detected by sensors embedded inside the holder are captured and sent to the server for analysis.~(used only during the test visits)~Participants had to brush their teeth at home (using toothbrushes with a flat-trimmed nylon bristle of identical type and length.) for 3 min thrice daily, after meals, as recommended by the Korean Dental Association.
Study NCT04627324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional toothbrush
Description: toothbrushes with a flat-trimmed nylon bristle of identical type and length.~Participants had to brush their teeth at home for 3 min thrice daily, after meals, as recommended by the Korean Dental Association.
Study NCT01827774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis® Soft Tissue Graft
Description: Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
Study NCT01011491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medifast 5 & 1 Plan for weight loss and weight maintenance
Description: Medifast's 5 \& 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
Study NCT01011491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food-based diet plan for weight loss and weight maintenance
Description: The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 \& 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
Study NCT03822312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBT-TOBI
Description: The DBT-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through
Study NCT03822312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-TOBI
Description: The MRI-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through. The MRI scan is completed at the same time as the TOBI scan. Participation in this part of the intervention is optional.
Study NCT02056314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brochure
Description: The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
Study NCT01714635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis Multifocal Intraocular Lens
Study NCT01714635 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal Intraocular Lens
Study NCT02601508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Continuous infusion of rocuronium for PTC 1 + Sugammadex
Study NCT02601508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cis-atracurium
Description: Intermittent injection of cis-atracurium for TOF 1 + Pyridostigmine \& Glycopyrrolate
Study NCT01917474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low lipid diet
Description: Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
Study NCT01917474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low lipid diet
Description: Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
Study NCT01917474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: normal lipid diet
Description: Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
Study NCT01917474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: normal lipid diet
Description: Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
Study NCT03240614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-rebreather oxygen mask
Description: This intervention will be preoxygenation using a Non-rebreather that will be placed upon the participant for preoxygenation. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After 3 minutes, an ABG will be taken and labeled as Intervention A.
Study NCT03240614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bag-valve-mask
Description: This intervention will be preoxygenation using a BVM apparatus for preoxygenation for 3 minutes. At the end of 3 minutes an ABG will be obtained.
Study NCT03240614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannulae
Description: This intervention will be preoxygenation using High Flow Nasal Cannulaes at an FiO2 of 100%. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After the 3 minutes, an ABG will be taken and labeled as Intervention C.
Study NCT01782495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Study NCT01782495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir
Study NCT01782495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet
Study NCT02645110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MC Hand Soap
Description: Washing hand with soap in comparison to hand washing with water alone
Study NCT02645110 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tap water
Description: Washing hand with water alone in comparison to hand washing with soap
Study NCT00790855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Starting dose of 50 mg/m\^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
Study NCT00303277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin 40 mg tablets once per day for 12 weeks
Study NCT00303277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin
Description: pravastatin 80 mg tablets once per day for 12 weeks
Study NCT01092611 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood collection
Description: Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
Study NCT01092611 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GSK HIV vaccine 732462
Description: No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
Study NCT02385552 — intervention group
Intervention type: BEHAVIORAL
Intervention: Feedback
Description: Experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rates.
Study NCT00576108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD7040 Topical Gel
Description: KD7040 topical gel
Study NCT00576108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel
Study NCT02173314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFE FC
Description: SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
Study NCT00999323 — intervention group
Intervention type: DEVICE
Intervention: stent implantation in coronary artery
Description: Percuatenous Coronary Intervention with implanatation of a stent
Study NCT00229723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib (Iressa)
Description: 250 mg oral tablet
Study NCT00229723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gefitinib (Iressa)
Description: 250 mg oral tablet
Study NCT00229723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: intravenous infusion
Study NCT06386250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional block
Description: In group A, iliohypogastric and ilioinguinal nerves were blocked by using 0.25% bupivacaine 2ml/kg of combined with skin infiltration of adrenaline 1:200 000.
Study NCT06386250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional block
Description: In group A, iliohypogastric and ilioinguinal nerves were blocked by using 0.25% bupivacaine 2ml/kg of combined with skin infiltration of adrenaline 1:200 000.
Study NCT06386250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: In group B 0.25% bupivacaine 0.5ml/Kg was infiltrated at the surgical site.
Study NCT06386250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal block
Description: In group B 0.25% bupivacaine 0.5ml/Kg was infiltrated at the surgical site.
Study NCT06386250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: In group C 0.25% Bupivacaine 1ml /kg was given into epidural space at L4-L5 or L5-S1.
Study NCT06386250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural
Description: In group C 0.25% Bupivacaine 1ml /kg was given into epidural space at L4-L5 or L5-S1.
Study NCT04742296 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: low level laser therapy
Description: We will use laser light that has continuous wave mode, power of 100 mW, energy density of 7,5 joule/cm2, treatment time as 300 seconds.
Study NCT04742296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy
Description: We will use laser light that has continuous wave mode, power of 100 mW, energy density of 7,5 joule/cm2, treatment time as 300 seconds.
Study NCT03236974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arm - Fulvestrant
Description: 500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock
Study NCT00229723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: intravenous infusion
Study NCT03236974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496
Description: Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
Study NCT00905398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 400mg, Oral, Bid, Daily for three years
Study NCT05573789 — intervention group
Intervention type: GENETIC
Intervention: Tumor molecular profiling
Description: Tumor molecular profiling was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic
Study NCT04740502 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Parahtyroidectomy
Description: Parathyroidectomy
Study NCT01745172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid body excision
Description: This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation.
Study NCT05454592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Coping Online Outreach Program
Description: 3 videos and a resource library disseminated over the course of 9 weeks.
Study NCT02048787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Subjects will receive a single dose of 50 mg buparlisib.
Study NCT00928681 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Single dose-group A
Description: PF-00547659, single iv dose
Study NCT00928681 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multiple dose- Group B
Description: PF-00547659, multiple dose
Study NCT00928681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single dose-group A
Description: PF-00547659, single dose
Study NCT00928681 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Single dose-group A
Description: PF-00547659, single dose
Study NCT00928681 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multiple dose-Group B
Description: PF-00547659, multiple dose
Study NCT02669433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101 35 mg
Description: once daily, oral, 35-mg tablets
Study NCT02669433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101 70 mg
Description: once daily, oral, 35-mg tablets
Study NCT02669433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral, matching tablets
Study NCT04661657 — intervention group
Intervention type: OTHER
Intervention: Transthoracic echocardiogram (TTE)
Description: Subjects will undergo TTE imaging.
Study NCT04661657 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance (CMR) Imaging
Description: Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).
Study NCT00870571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose
Description: A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
Study NCT00229723 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: radiation therapy
Study NCT00229723 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiation therapy
Study NCT00870571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NorvasC® 10 mg Tablets
Description: B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
Study NCT02516683 — intervention group
Intervention type: OTHER
Intervention: Shigella sonnei infection
Description: A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
Study NCT00776958 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
Study NCT02421315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment
Description: CBT treatment consisted of 12-16 hour-long sessions. For exceptional cases not showing clinical improvement after six CBT treatment sessions, complementary pharmacological treatment (SSRI) was offered as part of our treatment protocol. CBT for OCD involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
Study NCT02883153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium-89 girentuximab PET/CT
Description: Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
Study NCT04203784 — intervention group
Intervention type: OTHER
Intervention: Plasma concentration measurements
Description: Plasma concentration measurements
Study NCT04077645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun salutations
Description: This group will be asked to participate in 25 minutes of low-to-moderate intensity Yoga. This acute session will include engaging in sun salutations, breathing exercises and relaxation. Sun salutations involves performing 10 postures in a particular sequence, and then repeating that sequence. Some of the positions include bending over and touching one's toes, and lying belly-down on the ground and pushing up from ground while arching backwards. The activity will begin as a low intensity activity for the first 5 minutes, and the intensity will be gradually increased. Participants' heart rate will be measured before and after the intervention. The intervention will be delivered by a video displayed on a tablet device. An orientation session in the beginning will familiarize participants with the activity.
Study NCT04077645 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: This group will be asked to walk on the treadmill for the same amount of time (i.e. 25 minutes) at a moderate intensity (50-70% of their maximum heart rate). Participants will receive an initial 5-minute orientation and then begin at a self-selected speed for the first 5 minutes. Heart rate will be measured and monitored by an undergraduate research assistant. Speed will be increased after 5 minutes if participants have not reached the moderate zone. If participants still have not reached the target heart rate zone by the 10-min mark, the incline of the treadmill will be increased by a 5% grade until the zone is reached.
Study NCT00229723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib (Iressa)
Description: 500 mg oral tablet
Study NCT00229723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gefitinib (Iressa)
Description: 500 mg oral tablet
Study NCT00751556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium 660mg
Description: Extended release Naproxen Sodium (660mg) administered once a day
Study NCT00751556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Aleve 220 mg
Description: Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
Study NCT03521843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon dilation only
Description: The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
Study NCT03521843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon dilation+local drug delivery
Description: The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
Study NCT02156167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP810 and Codacs™ system test
Description: Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)